On 20 December 2024, Fresenius Kabi announced that it had entered into a licensing agreement with SamChunDang Pharm (SCD) to exclusively commercialise South Korean developed SCD-411, biosimilar to Regeneron’s Eylea® (aflibercept), in the United States, Brazil, Argentina, Chile, Paraguay, Colombia, and Mexico. SCD is responsible for the development, manufacture, and supply of SCD-411.
This licensing deal follows news in March this year that SCD entered an exclusive distribution agreement with an unnamed distributor to supply SCD-411 in the UK, Belgium, the Netherlands, Norway, Portugal, Sweden, Greece, Ireland, and Finland. SCD-411 was also the subject of an exclusive distribution agreement reported in November 2023, between SCD and an unnamed distributor, for supply to Austria, Germany, Italy, Spain, and Switzerland. SCD has licensed SCD411 to Apotex for the Canadian market.